功能协同化仿生基因编辑载体系统及其制备方法和应用
By constructing a biomimetic lipid carrier that resists protein adsorption, targets cancer cells, and delivers via membrane fusion, and encapsulating CXCL9 protein and a CRISPR system that dual-edits tumor cell genes, the problems of unstable delivery and insufficient targeting of CRISPR/Cas9 in liver cancer treatment were solved, achieving highly efficient liver cancer gene editing and anti-tumor effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
- Filing Date
- 2025-09-10
- Publication Date
- 2026-07-17
AI Technical Summary
Existing CRISPR/Cas9 gene editing systems suffer from problems such as unstable delivery, low targeting, and insufficient intracellular release efficiency in liver cancer treatment, which limits the therapeutic effect.
We constructed a biomimetic lipid carrier with anti-protein adsorption, cancer cell targeting, and membrane fusion delivery capabilities. This carrier encapsulated the CXCL9 protein factor and the dual-edited tumor cell genes BAG3 and HSP70 in a CRISPR system, forming a multifunctional synergistic biomimetic gene editing vector system that achieves the stability, precision, and efficiency of the CRISPR system.
It improves the gene editing efficiency of liver cancer cells, creates a powerful anti-tumor microenvironment, enhances the killing effect of T cells, and realizes the effective anti-cancer effect of the CRISPR system in the tumor environment.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3